---
title: "Pfizer Inc. $PFE Shares Bought by M.E. Allison & CO. Inc."
description: "M.E. Allison & CO. Inc. increased its holdings in Pfizer Inc. (NYSE:PFE) by 44.5% in Q2, now owning 36,348 shares valued at $881,000. Other institutional investors also adjusted their stakes. Analysts"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260881795.md"
published_at: "2025-10-13T10:57:01.000Z"
---

# Pfizer Inc. $PFE Shares Bought by M.E. Allison & CO. Inc.

> M.E. Allison & CO. Inc. increased its holdings in Pfizer Inc. (NYSE:PFE) by 44.5% in Q2, now owning 36,348 shares valued at $881,000. Other institutional investors also adjusted their stakes. Analysts have mixed ratings on Pfizer, with a consensus rating of "Hold" and an average price target of $28.35. Pfizer's stock opened at $24.81, with a market cap of $141.03 billion. The company reported $0.78 EPS for Q2, exceeding estimates, and announced a quarterly dividend of $0.43, payable on December 1st.

M.E. Allison & CO. Inc. raised its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 44.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 36,348 shares of the biopharmaceutical company's stock after acquiring an additional 11,186 shares during the quarter. M.E. Allison & CO. Inc.'s holdings in Pfizer were worth $881,000 as of its most recent filing with the Securities and Exchange Commission.

-   MarketBeat Week in Review – 10/06 - 10/10

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Bessemer Group Inc. lifted its stake in Pfizer by 11.1% during the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock valued at $3,358,000 after buying an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK lifted its stake in Pfizer by 1.2% during the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after buying an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp purchased a new stake in Pfizer during the first quarter valued at about $8,283,000. Westbourne Investments Inc. purchased a new stake in Pfizer during the first quarter valued at about $2,411,000. Finally, Bourne Lent Asset Management Inc. lifted its stake in Pfizer by 90.8% during the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company's stock valued at $927,000 after buying an additional 18,200 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

## Wall Street Analysts Forecast Growth

A number of analysts have commented on PFE shares. UBS Group reaffirmed a "neutral" rating and set a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Morgan Stanley reduced their price objective on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating for the company in a research note on Friday. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a research note on Wednesday, October 8th. Bank of America increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research report on Friday, October 3rd. Finally, Wall Street Zen lowered shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $28.35.

-   5 Healthcare Plays Powering the Sector’s Big Comeback

**Check Out Our Latest Research Report on Pfizer**

## Pfizer Trading Down 1.7%

Shares of PFE stock opened at $24.81 on Monday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $29.82. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business's 50 day moving average is $24.86 and its two-hundred day moving average is $24.12. The company has a market cap of $141.03 billion, a PE ratio of 13.19, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55.

-   Why AbbVie and Johnson & Johnson Could Outperform Pfizer

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter last year, the company posted $0.60 earnings per share. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

## Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer's dividend payout ratio (DPR) is presently 91.49%.

## Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

## Featured Articles

-   Five stocks we like better than Pfizer
-   Manufacturing Stocks Investing
-   Microsoft 365 Premium Marks the Next Phase of AI Monetization
-   Options Trading - Understanding Strike Price
-   Could Target’s Week of Discounts Come Full Circle for Investors?
-   ESG Stocks, What Investors Should Know
-   3 Reasons to Buy Sprouts Farmers Market Ahead of Earnings

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Pfizer Right Now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [PFE.US - Pfizer](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Daiwa downgrades Pfizer (PFE) to neutral following full-year 2025 earnings | Daiwa has downgraded Pfizer (PFE) to a neutral rating after the company's Q4 2025 earnings report, which showed $17.6 bi | [Link](https://longbridge.com/en/news/275968662.md) |
| Pfizer Announces Positive Phase 2b Results for Investigational Obesity Drug PF-08653944 | Pfizer Inc. has announced positive results from the Phase 2b VESPER-3 clinical trial for its investigational obesity dru | [Link](https://longbridge.com/en/news/274647411.md) |
| Cibc World Market Inc. Invests $1.22 Million in QXO, Inc. $QXO | Cibc World Market Inc. has invested $1.22 million in QXO, Inc. by acquiring 64,153 shares during Q3, as reported in its  | [Link](https://longbridge.com/en/news/276106337.md) |
| GSA Capital Partners LLP Buys Shares of 13,018 Ollie's Bargain Outlet Holdings, Inc. $OLLI | GSA Capital Partners LLP acquired 13,018 shares of Ollie's Bargain Outlet Holdings, Inc. (NASDAQ:OLLI) in Q3, valued at  | [Link](https://longbridge.com/en/news/276211459.md) |
| Envestnet Asset Management Inc. Purchases 62,803 Shares of WisdomTree, Inc. $WT | Envestnet Asset Management Inc. increased its stake in WisdomTree, Inc. by 6.9% in Q3, acquiring 62,803 shares, bringing | [Link](https://longbridge.com/en/news/276105675.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
